Alessia Zorz

Dr. Alessia Zorz

Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Neonatal Intensive Care Unit, Via della Commenda 12, 20122 Milan, Italy
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in International Journal of Nursing Studies
Verified
Journal Article
Closed access
GSG. Sorrentino
G. Sorrentino
MFM. Fumagalli
M. Fumagalli
SMS. Milani
S. Milani
ICI. Cortinovis
I. Cortinovis
AZAlessia Zorz
Alessia Zorz
LPL. Plevani
L. Plevani

26 November 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
IAilaria amodeo
ilaria amodeo
NPNicola Pesenti
Nicola Pesenti
GRGenny Raffaeli
Genny Raffaeli
GSGabriele Sorrentino
Gabriele Sorrentino
AZAlessia Zorz
Alessia Zorz
Giacomo CavallaroGiacomo Cavallaro
Giacomo Cavallaro
Background: The medication process in the Neonatal Intensive Care Unit (NICU), can be challenging in terms of costs, time, and the risk of errors. Newborns, especially if born preterm, are more vulnerable to medication errors than adults. Recently, robotic medication compounding has reportedly improved the safety and efficiency of the therapeutic process. In this study, we analyze the advantages of using the I.V. Station® system in our NICU, compared to the manual preparation of injectable drugs in terms of accuracy, cost, and time. Method: An in vitro experimental controlled study was conducted to analyze 10 injectable powdered or liquid drugs. Accuracy was calculated within a 5% difference of the bottle weight during different stages of preparation (reconstitution, dilution, and final product). The overall cost of manual and automated preparations were calculated and compared. Descriptive statistics for each step of the process are presented as mean ± standard deviation or median (range). Results: The median error observed during reconstitution, dilution, and final therapy of the drugs prepared by the I.V. Station® ranged within ±5% accuracy, with narrower ranges of error compared to those prepared manually. With increasing preparations, the I.V. Station® consumed less materials, reduced costs, decreased preparation time, and optimized the medication process, unlike the manual method. In the 10 drugs analyzed, the time saved from using the I.V. Station® ranged from 16 s for acyclovir to 2 h 57 min for teicoplanin, and cost savings varied from 8% for ampicillin to 66% for teicoplanin. These advantages are also capable of continually improving as the total amount of final product increases. Conclusions: The I.V. Station® improved the therapeutic process in our NICU. The benefits included increased precision in drug preparation, improved safety, lowered cost, and saved time. These advantages are particularly important in areas such as the NICU, where the I.V. Station® could improve the delivery of the high complexity of care and a large amount of intravenous therapy typically required. In addition, these benefits may lead to the reduction in medication errors and improve patient and family care; however, additional studies will be required to confirm this hypothesis.

23 November 2021 in Children
Verified
Journal Article
Open access
PDF file
Silvia FerrarioSilvia Ferrario
Silvia Ferrario
AZAlessia Zorz
Alessia Zorz
GSGabriele Sorrentino
Gabriele Sorrentino
SVstefania villa
stefania villa
RCRiccardo Cavalli
Riccardo Cavalli
SGStefano Ghirardello
Stefano Ghirardello
Background: A Pressure Ulcer (PU) is a severe event and could create discomfort to newborns. In newborns, one of mostly stricken location by PU is occipital area. Recent studies have highlighted that Cord Blood Platelet Gel (CBPG) might be a better alternative compared to traditional treatment. We report two cases of occipital PU treated with CBPG. Case report: Two male infants showing occipital PU were treated with standard local treatment, but no improvement was observed. After parental informed consent was obtained, CBPG application on PU was performed every 48 h. In these two cases of PU, a fast improvement in healing was observed since the first application of CBPG. The PU healed resulted in a scar after 53 and 50 days (Case 1 and Case 2, respectively) from development. No complications or infections were reported. Conclusions: CBPG contains many angiogenetic and growth factors, these characteristics make it indicated in treating soft tissue injuries. It would seem to be safe and an effective treatment of neonatal PUs reducing the time of the healing and the hospitalization and the infectious risks. Further studies are needed to evaluate long term aesthetic and functional results of PU treated with CBPG.